Neuropeptides xxx (2015) xxx–xxx

Contents lists available at ScienceDirect

Neuropeptides

journal homepage: www.elsevier.com/locate/ynpep

The role of the neuropeptide Y (NPY) family in the pathophysiology of inflammatory bowel disease (IBD)

Magdy El-Salhy [a,b,c,*], Trygve Hausken [b,c]

[a] Section for Gastroenterology, Department of Medicine, Stord Hospital, Stord, Norway
[b] Section for Neuroendocrine Gastroenterology, Division of Gastroenterology, Department of Clinical Medicine, University of Bergen, Bergen, Norway
[c] National Centre for Functional Gastrointestinal Disorders, Department of Medicine, Haukeland University Hospital, Bergen, Norway

ARTICLE INFO

Article history:
Received 29 June 2015
Received in revised form 11 September 2015
Accepted 15 September 2015
Available online xxxx

Keywords:
Crohn's disease
Inflammatory bowel disease
Motility
Secretion
Ulcerative colitis

ABSTRACT

Inflammatory bowel disease (IBD) includes three main disorders: ulcerative colitis, Crohn's disease, and microscopic colitis. The etiology of IBD is unknown and the current treatments are not completely satisfactory. Interactions between the gut neurohormones and the immune system are thought to play a pivot role in inflammation, especially in IBD. These neurohormones are believed to include members of the neuropeptide YY (NPY) family, which comprises NPY, peptide YY (PYY), and pancreatic polypeptide (PP). Understanding the role of these peptides may shed light on the pathophysiology of IBD and potentially yield an effective treatment tool. Intestinal NPY, PYY, and PP are abnormal in both patients with IBD and animal models of human IBD. The abnormality in NPY appears to be primarily caused by an interaction between immune cells and the NPY neurons in the enteric nervous system; the abnormalities in PYY and PP appear to be secondary to the changes caused by the abnormalities in other gut neurohormonal peptides/amines that occur during inflammation. NPY is the member of the NPY family that can be targeted in order to decrease the inflammation present in IBD.

Contents

1. Introduction

Inflammatory bowel disease (IBD) comprises three main disorders: ulcerative colitis (UC), Crohn's disease (CD), and microscopic colitis (MC). These disorders exhibit distinct clinical courses, organ specificities, and histopathological features (El-Salhy et al. 2012a, 2013a). UC, CD, and MC are chronic diseases; and while UC and CD patients experience infrequent relapses with years of complete remission, frequent relapses, or chronic active disease, MC patients typically experience chronic active disease (Danese and Fiocchi 2006; El-Salhy et al. 2013a; Nunes et al. 2011). The inflammation in CD is transmural in nature and occurs in any part of the gastrointestinal tract, while the inflammation in UC is more superficial and affects the rectocolonic mucosa, and the inflammation in MC manifests as mucosal and submucosal infiltration of immune cells without ulcerations or crypt abscesses and occurs in the colon (El-Salhy et al. 2012a, 2013a). In contrast to UC and CD, spontaneous symptomatic remission in MC has been reported to occur in 59–93% of the patients (Baert et al. 1999; Mullhaupt et al. 1998). The onset of UC and CD occurs more commonly at a young age

* Corresponding author at: Section for Gastroenterology, Department of Medicine, Stord Hospital, Box 4000, 54 09 Stord, Norway.
E-mail addresses: magdy.el-salhy@helse-fonna.no (M. El-Salhy), Trygve.hausken@helse-bergen.no (T. Hausken).

http://dx.doi.org/10.1016/j.npep.2015.09.005

(i.e., <40 years), whereas the onset of MC generally occurs in the elderly (i.e., >60 years) (Carter et al. 2004; El-Salhy et al. 2013a). In addition to the morbidity associated with IBD, it has a marked negative impact on the quality of life (El-Salhy et al. 2013a; Podolsky 2002a, 2002b).

The etiology of IBD is unknown and the current treatments are not completely satisfactory (El-Salhy et al. 2012a, 2013a). Treatments with 5-aminosalicylates and corticosteroids are not effective for most patients over the long term (El-Salhy et al. 2012a), and the short- and long-term side effects of the thiopurine analogs mercaptopurine, azathioprine, and methotrexate restrict their use (El-Salhy et al. 2012a). Biological agents such as antibodies against tumor necrosis factor (TNF) α are effective in only about 65% of UC and CD patients. Surgical treatment can result in malnutrition and eventual short-bowel syndrome in CD patients, and severe diarrhea in UC patients (El-Salhy et al. 2012a).

The interaction between the neuroendocrine peptides/amines of the gut and the immune system has been the focus of recent research, and it has been suggested that this interaction plays an important role in the pathophysiology of IBD (Ameri and Ferone 2012; Bampton and Dinning 2013; Farzi et al. 2015; Khan and Ghia 2010; Margolis and Gershon 2009). It is believed that an improved understanding of the role of the gut neuroendocrine peptides/amines in IBD will lead to the application of agonists or antagonists to these peptides/amines that represent a potentially significant therapeutic opportunity in IBD. The role of the neuropeptide Y (NPY) family in IBD has been discussed previously (El-Salhy et al. 2013b; El-Salhy et al. 2002; Vona-Davis and McFadden 2007; Wheway et al. 2007a, 2007b; Wheway et al. 2005). The present review summarizes the available data on the NPY family in IBD and speculates on its role in the pathophysiology of this disease.

2. The NPY family of peptides

The NPY family comprises three peptides—namely NPY, peptide YY (PYY), and pancreatic polypeptide (PP) (Adrian et al. 1985; Tatemoto 1982a, 1982b; Tatemoto and Mutt 1980; Tatemoto et al. 1985)—that act as hormones and/or neurotransmitters/neuromodulators. These peptides consists of 36 amino acid residues and are structurally related (Vona-Davis and McFadden 2007). NPY is expressed in multiple neuronal systems of the brain, from the medullary brainstem to the cerebral cortex, and in enteric neurons including secretomotor and inhibitory motoneurones (Brumovsky et al. 2007; Eaton et al. 2007; Kask et al. 2002; Tatemoto 1982b; Tatemoto et al. 1985; Vona-Davis and McFadden 2007; Wettstein et al. 1995), while PYY and PP are localized in endocrine cells in the ileum, colon, and rectum (El-Salhy et al. 1983a; El-Salhy et al. 1982; El-Salhy et al. 1983b). PP is also found in endocrine cells in the pancreatic islets of Langerhans (Adrian et al. 1985).

All three peptides belonging to the NPY family exert their actions by binding to at least six Y-receptor subtypes of transmembrane G-protein-coupled receptors (Vona-Davis and McFadden 2007). Five Y receptors are expressed in mammals (including humans), namely Y_1, Y_2, Y_4, Y_5, and Y_6 (Farzi et al. 2015). NPY and PYY bind to and activate receptors Y_1, Y_2, and Y_5, and PP binds to receptor Y_4 (Cox et al. 2001; Cox and Tough 2002; Hyland and Cox 2005; Hyland et al. 2003). Receptors Y_1, Y_2, and Y_4 have been found in the colon and small intestine, localized to epithelial cells and neurons belonging to the submucosal and myenteric plexus (Cox et al. 2001; Cox and Tough 2002; Gregor et al. 1996a; Gregor et al. 1996b; Gue et al. 1996; Inui et al. 1992; Mao et al. 1996; Sheikh and Williams 1990; Walsh et al. 1993; Wharton et al. 1993; Yan et al. 1996).

The NPY family of peptides exerts multiple physiological effects upon binding to their receptors. NPY and PYY exert similar biological effects, which differ from the effects of PP. NPY and PYY delay gastric emptying and are mediators of the ileal brake; they also inhibit gastric and pancreatic secretion, and stimulate the absorption of water and electrolytes (El-Salhy et al. 2014; El-Salhy et al. 2012d; Vona-Davis and McFadden 2007). The effects of NPY in the gut are much less potent than those of PYY (Gomez et al. 1995). PP stimulates gastric acid secretion and the motility of the stomach and small intestine, relaxes the gallbladder, and inhibits pancreatic secretion (El-Salhy et al. 2014; El-Salhy et al. 2012d).

All members of the NPY peptide family play a pivotal role in regulating the appetite and food intake (Konturek et al. 2004; Nguyen et al. 2011). NPY is expressed in two populations of neurons in the arcuate nucleus (ARC) of the hypothalamus: (1) those expressing both NPY and AgRP (Agouti-related peptide), and (2) those containing NPY and POMC (the pro-opiomelanocortin and cocaine and amphetamine-regulated transcript)—the former neurons stimulate food intake while the latter suppress it (Ellacott and Cone 2004; Nguyen et al. 2011; Ollmann et al. 1997). The ARC lies in the median eminence, which lacks a complete blood–brain barrier and is thus susceptible to factors circulating in the blood (Cone et al. 2001; Peruzzo et al. 2000; Yu 2012). The ARC is the center for integrating neurological and blood-borne signals. Similarly, the brainstem is proximal to other regions with an incomplete blood–brain barrier, thus allowing it to receive blood-borne signals (Chaudhri et al. 2006; Yu 2012). PYY is released into the circulation in response to meal ingestion (Adrian et al. 1985). Infusing $PYY_{3\text{-}36}$ was found to reduce food consumption during test meals. Moreover, obese subjects were shown to have a low plasma level of PYY (Batterham et al. 2003; Batterham et al. 2002). Circulating $PYY_{3\text{-}36}$ binds to the Y_2 receptors on the presynaptic terminals of hypothalamic NPY neurons, inactivating them and resulting in the induction of anorexia (Michel et al. 1998). By regulating the ileal break, PYY inhibits further food intake once nutrients have reached the distal small intestine (ileum) (Lin et al. 1996a, 1997; Lin et al. 1996b; Maljaars et al. 2007; Maljaars et al. 2008a; Maljaars et al. 2008b; Ohtani et al. 2001; Pironi et al. 1993; Van Citters and Lin 1999, 2006). Similar to PYY, PP reduces appetite and food intake (Jesudason et al. 2007; Zhang et al. 2012).

3. The NPY family and inflammation

The sympathetic neurons that innervate lymphoid organs contain NPY, which is co-released with norepinephrine upon stimulation (Lundberg et al. 1989; Romano et al. 1991). NPY is produced by T lymphocytes, macrophages, monocytes, and dendritic cells during inflammation, and it modulates the immune cell activities via a paracrine or autocrine mode of action (Macia et al. 2012; Schwarz et al. 1994; Wheway et al. 2005). The Y_1 and Y_2 receptors are localized on immune cells including macrophages, neutrophils, granulocytes, and lymphocytes, with the Y_1 receptor being the most abundant (Bedoui et al. 2008; Chandrasekharan et al. 2013b; Dimitrijevic et al. 2005; Dimitrijevic and Stanojevic 2013; Dimitrijevic et al. 2010; Singer et al. 2013). The binding of NPY to these receptors influences the activities of the immune cells (Farzi et al. 2015; Petitto et al. 1994) in either a pro- or an anti-inflammatory manner (Farzi et al. 2015; Wheway et al. 2005). NPY plays a distinctive role in the immunity of the gastrointestinal tract since NPY nerve fibers are in close contact with immune cells (Shibata et al. 2008), and there is compelling evidence that NPY exerts a proinflammatory action in the gut (Chandrasekharan et al. 2008; Chandrasekharan et al. 2013a; Farzi et al. 2015; Hassani et al. 2005; Holzer et al. 2012; Painsipp et al. 2011; Pang et al. 2010; Wheway et al. 2005).

PYY mRNA has been found in mouse macrophages (Macia et al. 2012), and PYY increases the adhesion of macrophages, chemotaxis, phagocytosis, and production of superoxide anions (De la Fuente et al. 1993). The exact role of PP in inflammation has not yet been determined.

4. Abnormalities in the NPY family in IBD

The induction of colitis in mice using either dextran sodium sulfate (DSS) or *Salmonella-typhimurium*-pretreated streptomycin lead to an increase in NPY enteric neurons and hyperplasia of NPY nerve fibers (Bjorck et al. 1997; Chandrasekharan et al. 2008). Surgical resection of

Please cite this article as: El-Salhy, M., Hausken, T., The role of the neuropeptide Y (NPY) family in the pathophysiology of inflammatory bowel disease (IBD), Neuropeptides (2015), http://dx.doi.org/10.1016/j.npep.2015.09.005